Simon MEGY
Equipe : Groupe EcMo
Courriel : simon.megy@ibcp.fr
Téléphone : +33(0)4-72-72-26-55
Statut : Maître de conférences
12 publications au total. Seules les 5 dernières années sont affichées
2023
12. Induction of a strong and long-lasting neutralizing immune response by dPreS1-TLR2 agonist nanovaccine against hepatitis B virus.
Lamrayah M, Charriaud F, Desmares M, Coiffier C, Megy S, Colomb E, Terreux R, Lucifora J, Durantel D, Verrier B
(2023) Antiviral Res 209 :105483-105483
2021
11. Discovery of a Novel Non-Narcotic Analgesic Derived from the CL-20 Explosive: Synthesis, Pharmacology, and Target Identification of Thiowurtzine, a Potent Inhibitor of the Opioid Receptors and the Ion Channels.
Aguero S, Megy S, Eremina Vv, Kalashnikov Ai, Krylova Sg, Kulagina Da, Lopatina Ka, Fournier M, Povetyeva Tn, Vorozhtsov Ab, Sysolyatin Sv, Zhdanov Vv, Terreux R
(2021) Acs Omega 6 :15400-15411
10. Surface charge modulation of rifampicin-loaded PLA nanoparticles to improve antibiotic delivery in Staphylococcus aureus biofilms.
Da Costa D, Exbrayat-héritier C, Rambaud B, Megy S, Terreux R, Verrier B, Primard C
(2021) J Nanobiotechnology 19 :12-12
2020
9. Molecular Dynamics Studies of Poly(Lactic Acid) Nanoparticles and Their Interactions with Vitamin E and TLR Agonists Pam1CSK4 and Pam3CSK4.
Megy S, Aguero S, Da Costa D, Lamrayah M, Berthet M, Primard C, Verrier B, Terreux R
(2020) Nanomaterials (basel) 10 :
2019
8. Molecular modelling of TLR agonist Pam(3)CSK(4) entrapment in PLA nanoparticles as a tool to explain loading efficiency and functionality.
Lamrayah M, Charriaud F, Hu S, Megy S, Terreux R, Verrier B
(2019) Int J Pharm 568 :118569-118569
2015
7. A Novel Alpha Cardiac Actin (ACTC1) Mutation Mapping to a Domain in Close Contact with Myosin Heavy Chain Leads to a Variety of Congenital Heart Defects, Arrhythmia and Possibly Midline Defects.
Augiere C, Megy S, El Malti R, Boland A, El Zein L, Verrier B, Megarbane A, Deleuze Jf, Bouvagnet P
(2015) Plos One 10 :e0127903-e0127903
6. A purified truncated form of yeast Gal4 expressed in Escherichia coli and used to functionalize poly(lactic acid) nanoparticle surface is transcriptionally active in cellulo.
Legaz S, Exposito Jy, Borel A, Candusso Mp, Megy S, Montserret R, Lahaye V, Terzian C, Verrier B
(2015) Protein Expr Purif 113 :94-101
2006
5. NMR studies for identifying phosphopeptide ligands of the HIV-1 protein Vpu binding to the F-box protein beta-TrCP.
Evrard-todeschi N, Gharbi-benarous J, Bertho G, Coadou G, Megy S, Benarous R, Girault Jp
(2006) Peptides 27 :194-210
4. STD and TRNOESY NMR studies for the epitope mapping of the phosphorylation motif of the oncogenic protein beta-catenin recognized by a selective monoclonal antibody.
Megy S, Bertho G, Gharbi-benarous J, Baleux F, Benarous R, Girault Jp
(2006) Febs Lett 580 :5411-22
2005
3. Solution structure of a peptide derived from the oncogenic protein beta-Catenin in its phosphorylated and nonphosphorylated states
Megy S, Bertho G, Gharbi-benarous J, Baleux F, Benarous R, Girault Jp
(2005) Peptides 26 :227-241
2. STD and TRNOESY NMR studies on the conformation of the oncogenic protein beta-catenin containing the phosphorylated motif DpSGXXpS bound to the beta-TrCP protein
Megy S, Bertho G, Gharbi-benarous J, Evrard-todeschi N, Coadou G, Segeral E, Iehle C, Quemeneur E, Benarous R, Girault Jp
(2005) Journal Of Biological Chemistry 280 :29107-29116
2003
1. NMR studies of the phosphorylation motif of the HIV-1 protein Vpu bound to the F-box protein beta-TrCP
Coadou G, Gharbi-benarous J, Megy S, Bertho G, Evrard-todeschi N, Segeral E, Benarous R, Girault Jp
(2003) Biochemistry 42 :14741-14751
